MN HF2533

Expands the exemption from prior authorization and utilization management controls for mental health medications from only atypical antipsychotics to all central nervous system drugs classified as anticonvulsants, antidepressants, antipsychotics, or noncontrolled substance antianxiety drugs prescribed for mental illness treatment

Removes previous conditions that limited the exemption to drugs with no generic equivalent, drugs initially prescribed before July 1, 2003, or drugs that were part of a recipient's current treatment course

Requires automatic 60-day prior authorization approval for brand name mental health drugs when a generic equivalent becomes available, if the brand name was part of the recipient's ongoing treatment

Adds a definition of "utilization management controls" to include formal techniques used to monitor prescription drug use or evaluate medical necessity, including prior authorization and step therapy protocols

Applies these expanded exemptions to any multistate preferred drug list or supplemental drug rebate program administered by the commissioner